Dr. Richard Larson
Hematology & Oncology (Hematology & Oncology Physician)
5841 S Maryland Ave
Chicago, IL 60637
Who else practices at this address →
Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Stanford University School of Medicine (1977)
- Years since graduation
- 49
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 95
Licensed in Illinois since 1978, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1977Medical school: Stanford University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
IL license 036057429 (first issued 1978; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- The University of Chicago Medical Center Chicago, IL
Medical groups
- University of Chicago (1,712 clinicians)
- The University of Chicago Medical Center (915 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 95
- Services billed
- 261
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 302 | 43 |
| Established patient office or other outpatient visit, 40-54 minutes | 51 | 22 |
| Established patient office or other outpatient visit, 20-29 minutes | 40 | 31 |
| Established patient office or other outpatient visit, 30-39 minutes | 34 | 23 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 33 | 28 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 14 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Imatinib Mesylate | 36 |
| Calquence (acalabrutinib maleate) | 34 |
| Sprycel (dasatinib) | 21 |
| Hydroxyurea Other prescribers in Chicago, IL | 18 |
| Acyclovir Other prescribers in Chicago, IL | 13 |
| Iclusig (ponatinib hcl) | 13 |
| Tasigna (nilotinib hcl) | 11 |
| Venclexta (venetoclax) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $757 in total to this clinician.
| Epizyme, Inc. | $638 |
|---|---|
| Novartis Pharmaceuticals Corporation | $120 |
| Consulting Fee | $638 |
|---|---|
| Food and Beverage | $120 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Epizyme, Inc. May 21, 2025 | Consulting Fee Tazverik · Oncology | $638 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $133,448 in research payments for these studies, mostly to the institutions running them.
- A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AM…
Astellas Pharma Global Development - A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia
Novartis Pharmaceuticals Corporation - Ph2 multi center open label randomized study in CML CP patients previously treated with imatinib and not achieved DMR asciminib imatinib vs continued imatinib vs switch to nilotinib
Novartis Pharmaceuticals Corporation - Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Daiichi Sankyo Inc. · Active, not recruiting · NCT06578247
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.